[go: up one dir, main page]

MX2014005090A - Derivado de n-tienilbenzamida sustituido con aminoalquilo. - Google Patents

Derivado de n-tienilbenzamida sustituido con aminoalquilo.

Info

Publication number
MX2014005090A
MX2014005090A MX2014005090A MX2014005090A MX2014005090A MX 2014005090 A MX2014005090 A MX 2014005090A MX 2014005090 A MX2014005090 A MX 2014005090A MX 2014005090 A MX2014005090 A MX 2014005090A MX 2014005090 A MX2014005090 A MX 2014005090A
Authority
MX
Mexico
Prior art keywords
aminoalkyl
thienyl
substituted
represent
benzamide derivative
Prior art date
Application number
MX2014005090A
Other languages
English (en)
Other versions
MX342521B (es
Inventor
Susumu Watanuki
Ippei Sato
Masanori Miura
Daisuke Kaga
Shunichiro Hachiya
Takao Okuda
Mai Isomura
Kazuhiro Terai
Yoh Terada
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2014005090A publication Critical patent/MX2014005090A/es
Publication of MX342521B publication Critical patent/MX342521B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/68Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80Seven-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring
    • C07F9/655354Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

El objetivo de la presente invención es proporcionar un compuesto que tiene actividad inhibitoria contra un transportador intestinal de fosfato (NPT-Ilb, por sus siglas en inglés), y útil como ingrediente activo en un agente terapéutico de hiperfosfatemia y/o un medicamento profiláctico. Un compuesto de tiofeno representado por la fórmula (I) puede usarse como un agente terapéutico de hiperfosfatemia y/o un medicamento profiláctico que tiene actividad inhibitoria contra NPT-llb. (En la fórmula, cada uno de R1-6 representan H o un alquilo inferior o similar, cada uno de L1-4 representa un alquilo inferior o similar, X1 representa CH2 u O, cada uno de X2-3 representa CH o N, k es 1-3, y n es 0-1.).
MX2014005090A 2011-10-27 2012-10-25 Derivado de n-tienilbenzamida sustituido con aminoalquilo. MX342521B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011236533 2011-10-27
PCT/JP2012/077660 WO2013062065A1 (ja) 2011-10-27 2012-10-25 アミノアルキル置換n-チエニルベンズアミド誘導体

Publications (2)

Publication Number Publication Date
MX2014005090A true MX2014005090A (es) 2015-02-12
MX342521B MX342521B (es) 2016-10-03

Family

ID=48167891

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005090A MX342521B (es) 2011-10-27 2012-10-25 Derivado de n-tienilbenzamida sustituido con aminoalquilo.

Country Status (18)

Country Link
US (1) US9062032B2 (es)
EP (1) EP2772490B1 (es)
JP (2) JP2013107880A (es)
KR (1) KR101941048B1 (es)
CN (1) CN103906741B (es)
AR (1) AR088563A1 (es)
AU (1) AU2012329913A1 (es)
BR (1) BR112014010169B1 (es)
CA (1) CA2853688C (es)
EA (1) EA023955B1 (es)
ES (1) ES2585415T3 (es)
IL (1) IL232230A0 (es)
IN (1) IN2014CN03130A (es)
MX (1) MX342521B (es)
PH (1) PH12014500887A1 (es)
PL (1) PL2772490T3 (es)
TW (1) TW201323419A (es)
WO (1) WO2013062065A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3023415T3 (pl) * 2012-10-02 2018-06-29 Gilead Sciences, Inc. Inhibitory demetylaz histonowych
TWI596095B (zh) 2013-03-13 2017-08-21 中外製藥股份有限公司 Dihydropyridazine-3,5-dione derivatives
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
TWI594975B (zh) 2013-04-24 2017-08-11 第一三共股份有限公司 二羧酸化合物
WO2015018823A1 (en) 2013-08-08 2015-02-12 Galapagos Nv Thieno[2,3-c]pyrans as cftr modulators
WO2015064532A1 (ja) * 2013-10-30 2015-05-07 第一三共株式会社 モルホリン化合物
CA2943824A1 (en) * 2014-03-31 2015-10-08 Gilead Sciences, Inc. Inhibitors of histone demethylases
WO2016026372A1 (zh) * 2014-08-22 2016-02-25 江苏恒瑞医药股份有限公司 噻吩并环烷基或噻吩并杂环基类衍生物、其制备方法及其在医药上的应用
ES2881611T3 (es) 2014-09-12 2021-11-30 Chugai Pharmaceutical Co Ltd Producto farmacéutico que contiene inhibidor del transportador de fosfato dependiente de sodio
BR112017005694A2 (pt) 2014-09-26 2017-12-12 Daiichi Sankyo Co Ltd cristais de um sal, ou hidrato do mesmo, cristais de um trihidrato de sal dissódico, composição farmacêutica, uso dos cristais, e, método para prevenção ou tratamento de hiperfosfatemia.
CN105524053B (zh) * 2014-10-19 2020-06-05 广东东阳光药业有限公司 四氢苯并噻吩化合物
TW201700458A (zh) 2015-04-24 2017-01-01 第一三共股份有限公司 二羧酸化合物之製法
CN107082773B (zh) * 2016-02-16 2020-07-28 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的硫酸盐及其结晶形式
EA037376B1 (ru) 2016-08-15 2021-03-22 Эли Лилли Энд Компани Конденсированные тиофеновые производные, приемлемые в качестве ингибиторов napi-iib
JOP20190080A1 (ar) 2016-10-14 2019-04-11 Bayer Pharma AG مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها
CN109422723B (zh) * 2017-08-25 2021-02-23 江苏恒瑞医药股份有限公司 一种肠2b型磷酸钠协同转运蛋白抑制剂的晶型及其制备方法
AR126060A1 (es) 2021-06-08 2023-09-06 Chugai Pharmaceutical Co Ltd Método para producir derivado de dihidropiridazin-3,5-diona
AU2022288895A1 (en) 2021-06-08 2024-01-18 Chugai Seiyaku Kabushiki Kaisha Formulation containing dihydropyridazine-3,5-dione derivative
WO2023203254A2 (en) 2022-04-22 2023-10-26 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
EP4523703A1 (en) 2022-05-11 2025-03-19 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for treating or preventing cystic disease
WO2024223617A1 (en) 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002213048A1 (en) * 2000-10-05 2002-04-15 Smith Kline Beecham Corporation Phosphate transport inhibitors
JP2007131532A (ja) 2001-09-28 2007-05-31 Kirin Brewery Co Ltd 生体内リン輸送を阻害する化合物およびそれを含んでなる医薬
JPWO2003048134A1 (ja) 2001-12-05 2005-04-14 日本たばこ産業株式会社 トリアゾール化合物及びその医薬用途
EP1614676A4 (en) 2003-03-27 2009-03-25 Kirin Pharma Kk CONNECTION TO INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICAMENT CONTAINING THEREOF
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
AU2005279845A1 (en) 2004-08-30 2006-03-09 Government Of The United States Of America, As Represented By The Secretary Department Of Health And Human Services Inhibition of viruses using RNase H inhibitors
JP2008517061A (ja) 2004-10-20 2008-05-22 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー 抗腫瘍剤としての化合物及びそれらの使用
KR101343399B1 (ko) * 2008-01-08 2013-12-19 퍼듀 퍼머 엘피 통증 치료를 위한 카나비노이드 수용체에 대한 리간드로서의 프롤린 유사체
BR112012025390B8 (pt) 2010-04-28 2022-11-22 Astellas Pharma Inc Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto
JP5827326B2 (ja) 2010-07-07 2015-12-02 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
JP5823514B2 (ja) 2010-07-07 2015-11-25 アーデリクス,インコーポレーテッド リン酸輸送を阻害する化合物及び方法
EP2590965B1 (en) 2010-07-07 2016-04-20 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2590510B1 (en) 2010-07-07 2016-09-28 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP2591354B1 (en) 2010-07-07 2016-09-07 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport

Also Published As

Publication number Publication date
PH12014500887A1 (en) 2019-06-03
KR101941048B1 (ko) 2019-01-22
IN2014CN03130A (es) 2015-07-03
WO2013062065A1 (ja) 2013-05-02
CA2853688A1 (en) 2013-05-02
EP2772490B1 (en) 2016-04-06
IL232230A0 (en) 2014-06-30
EP2772490A1 (en) 2014-09-03
JPWO2013062065A1 (ja) 2015-04-02
US20150031727A1 (en) 2015-01-29
US9062032B2 (en) 2015-06-23
CA2853688C (en) 2018-06-12
CN103906741A (zh) 2014-07-02
AR088563A1 (es) 2014-06-18
KR20140096322A (ko) 2014-08-05
PL2772490T3 (pl) 2016-11-30
JP2013107880A (ja) 2013-06-06
EP2772490A4 (en) 2015-01-21
BR112014010169B1 (pt) 2021-12-07
JP6020460B2 (ja) 2016-11-02
MX342521B (es) 2016-10-03
EA201490875A1 (ru) 2014-09-30
CN103906741B (zh) 2016-01-20
BR112014010169A2 (pt) 2017-04-25
AU2012329913A1 (en) 2014-05-22
TW201323419A (zh) 2013-06-16
EA023955B1 (ru) 2016-07-29
ES2585415T3 (es) 2016-10-05

Similar Documents

Publication Publication Date Title
MX342521B (es) Derivado de n-tienilbenzamida sustituido con aminoalquilo.
EA201291121A1 (ru) Соединения тетрагидробензотиофена
EA201390198A1 (ru) Гетероциклическое соединение
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
IN2015MN00405A (es)
MX348422B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201201648A1 (ru) Стимуляторы sgc
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
NZ723198A (en) Anthelmintic compounds and compositions and methods of using thereof
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
EA026931B9 (ru) Гербицидно и фунгицидно действующие 5-оксизамещенные 3-фенилизоксазолин-5-карбоксамиды и 5-оксизамещенные 3-фенилизоксазолин-5-тиоамиды или их соли
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
BR112013021638A2 (pt) "compostos inibidores de trk, seu uso e composições que os compreendem"
MX356342B (es) Agente de control de endoparásitos y método para usarlo.
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MY170262A (en) Dicarboxylic acid compound
EA201790016A1 (ru) АНАЛОГ ПИРИДИНО[1,2-a]ПИРИМИДОНА, ПРИМЕНЯЕМЫЙ В КАЧЕСТВЕ ИНГИБИТОРА PI3K
MX2015000903A (es) Derivados de carbamato/urea.
MX348979B (es) Agente de control de enfermedades de las plantas.
BR112015027164A2 (pt) novos compostos com tripla atividade de trombólise, antitrombótica e neutralização de radical, e sua síntese, nanoestrutura e uso
PH12014501181A1 (en) N- (4 -quinolinylmethyl) sulfonamide derivatives and their use as anthelmintics
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2013106756A3 (en) Antimicrobial agents
PH12017501336B1 (en) Preventive and/or therapeutic agent of immune disease

Legal Events

Date Code Title Description
FG Grant or registration